文献速递白血病

来那度胺联合米托蒽醌、依托泊苷和阿糖胞苷再诱导治疗急性髓系白血病的I期研究

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2017-11-21

本研究为I期剂量递增研究,纳入35例复发/难治性急性髓系白血病成人患者,采用「3+3」设计,来那度胺联合MEC方案。来那度胺与MEC联合的最大耐受剂量为50 mg/d第1-10天,35例中12例达完全缓解(34%,90%CI 21-50%),中位总生存11.5个月;在最大耐受剂量治疗的17例中7例达完全缓解(41%),12个月总生存率61%。

要点

  • 来那度胺联合MEC的最大耐受剂量为50 mg/d第1-10天。
  • 35例中12例达完全缓解(34%,90%CI 21-50%),中位总生存11.5个月。
  • 最大耐受剂量组17例中7例达完全缓解(41%),12个月总生存率61%。

核心结论

  • MEC联合来那度胺可耐受,II期推荐剂量为来那度胺50 mg/d第1-10天,缓解率令人鼓舞。
  • 计划进一步研究来那度胺与MEC的潜在免疫调节作用。

研究设计与样本

  • I期剂量递增研究,纳入35例复发/难治性急性髓系白血病成人患者,采用「3+3」设计,并在最大耐受剂量下扩展10例。
  • 来那度胺初始为第1-14天给药、MEC第4-8天给药;因计数恢复延迟,方案修改为来那度胺第1-10天给药。
  • 来那度胺剂量从5 mg/d开始递增(5-10-25-50 mg/d)。
  • 主要终点为耐受性和最大耐受剂量确定,次要终点包括总生存。

主要发现

  • 来那度胺联合MEC的最大耐受剂量为50 mg/d第1-10天。
  • 35例入组患者中12例达完全缓解(34%,90%CI 21-50%);30天死亡率为6%,60天死亡率为13%。
  • 全部患者的中位总生存为11.5个月。
  • 在最大耐受剂量下治疗的17例患者中,7例达完全缓解(41%);中位总生存未达到,12个月总生存率为61%。
  • 接受MEC和来那度胺治疗后,患者CD4+和CD8+ T细胞对自体肿瘤裂解物的炎症反应增强。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed AML have a poor prognosis and limited responses to standard chemotherapy. Lenalidomide is an immunomodulatory drug that may modulate anti-tumor immunity. We performed a study to evaluate the safety and tolerability of lenalidomide with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory AML. Adult patients with relapsed/refractory AML were eligible for this phase I dose-escalation study. We enrolled 35 patients using a "3 + 3" design, with a 10 patient expansion cohort at the maximum tolerated dose (MTD). Lenalidomide was initially given days 1-14 and MEC days 4-8; due to delayed count recovery, the protocol was amended to administer lenalidomide days 1-10. The dose of lenalidomide was then escalated starting at 5 mg/d (5-10-25-50). The primary objective was tolerability and MTD determination, with secondary outcomes including overall survival (OS). The MTD of lenalidomide combined with MEC was 50 mg/d days 1-10. Among the 35 enrolled patients, 12 achieved complete remission (CR) (34%, 90%CI 21-50%); 30-day mortality was 6% and 60-day mortality 13%. The median OS for all patients was 11.5 months. Among 17 patients treated at the MTD, 7 attained CR (41%); the median OS was not reached while 12-month OS was 61%. Following therapy with MEC and lenalidomide, patient CD4+ and CD8+ T-cells demonstrated increased inflammatory responses to autologous tumor lysate. The combination of MEC and lenalidomide is tolerable with an RP2D of lenalidomide 50 mg/d days 1-10, yielding encouraging response rates. Further studies are planned to explore the potential immunomodulatory effect of lenalidomide and MEC.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. DeAngelo DJ, Brunner AM, Werner L, et al. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2017. PMID: 29119643. doi:10.1002/ajh.24968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。